|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **No. Participants** | | **No. Events** | | **Follow-up** | **Cummulative. Incidence per 10,000** | | **Central Estimate.  (HR or IRR)** | **95% CI** | **Ref** |
| **Outcome** | **Study** | **Exp.** | **Non Exp.** | **Exp.** | **Non Exp.** | **Exp.** | **Non Exp.** |
| Alopecia areata | Tesch, 2023 | 641407 | 1907992 | 198 | 152 |  | 30.87 | 7.97 | 1.30\* | 1.05-1.05 |  |
| Ankylosing spondylitis | Chang, 2023 | 887455 | 887455 | 243 | 82 |  | 27.38 | 9.24 | 3.21^ | 2.5-2.5 |  |
| Tesch, 2023 | 641407 | 1907992 | 263 | 194 |  | 41.00 | 10.17 | 1.36\* | 1.13-1.13 |  |
| Arteritis temporalis | Tesch, 2023 | 641407 | 1907992 | 53 | 33 |  | 8.26 | 1.73 | 1.63\* | 1.05-1.05 |  |
| Autoimm. hemolytic anemia | Tesch, 2023 | 641407 | 1907992 | 21 | 15 |  | 3.27 | 0.79 | 1.37\* | 0.71-0.71 |  |
| Autoimmune hepatitis | Tesch, 2023 | 641407 | 1907992 | 38 | 35 |  | 5.92 | 1.83 | 1.10\* | 0.69-0.69 |  |
| Behcet’s disease | Chang, 2023 | 887455 | 887455 | 45 | 21 |  | 5.07 | 2.37 | 2.32^ | 1.38-1.38 |  |
| Tesch, 2023 | 641407 | 1907992 | 21 | 9 |  | 3.27 | 0.47 | 2.42\* | 1.1-1.1 |  |
| Bullous pemphigoid | Tesch, 2023 | 641407 | 1907992 | 45 | 29 |  | 7.02 | 1.52 | 1.54\* | 0.97-0.97 |  |
| Crohn’s disease | Tesch, 2023 | 641407 | 1907992 | 298 | 235 |  | 46.46 | 12.32 | 1.27\* | 1.07-1.07 |  |
| Dermatopolymyositis | Chang, 2023 | 887455 | 887455 | 131 | 72 |  | 14.76 | 8.11 | 1.96^ | 1.47-1.47 |  |
| Encephalitis or encephalopathy | Xu, 2022 | 154068 | 5638795 |  |  |  |  |  | 1.82^ | 1.16-1.16 |  |
| Graves’ disease | Tesch, 2023 | 641407 | 1907992 | 1696 | 1207 |  | 264.42 | 63.26 | 1.41\* | 1.31-1.31 |  |
| Guillain-Barré syndrome | Mizrahi, 2023a | 162853 | 162853 | 11 | 11 |  | 6.75 | 6.75 | 1.12^ | 0.48-0.48 |  |
| Mizrahi, 2023b | 150609 | 150609 | 7 | 3 |  | 4.65 | 1.99 | 2.90^ | 0.72-0.72 |  |
| Tesch, 2023 | 641407 | 1907992 | 20 | 9 |  | 3.12 | 0.47 | 2.14\* | 0.99-0.99 |  |
| Xu, 2022 | 154068 | 5638795 |  |  |  |  |  | 2.16^ | 1.4-1.4 |  |
| Hashimoto thyroiditis | Tesch, 2023 | 641407 | 1907992 | 2089 | 1474 |  | 325.69 | 77.25 | 1.42\* | 1.33-1.33 |  |
| Inflammatory bowel disease | Chang, 2023 | 887455 | 887455 | 7945 | 4863 |  | 895.26 | 547.97 | 1.78^ | 1.72-1.72 |  |
| Mixed connective tissue disease | Chang, 2023 | 887455 | 887455 | 139 | 48 |  | 15.66 | 5.41 | 3.14^ | 2.26-2.26 |  |
| Multiple sclerosis | Tesch, 2023 | 641407 | 1907992 | 271 | 226 |  | 42.25 | 11.84 | 1.20\* | 1.01-1.01 |  |
| Myasthenia gravis | Tesch, 2023 | 641407 | 1907992 | 41 | 27 |  | 6.39 | 1.42 | 1.50\* | 0.93-0.93 |  |
| Polymyalgia rheumatica | Chang, 2023 | 887455 | 887455 | 330 | 123 |  | 37.18 | 13.86 | 2.90^ | 2.36-2.36 |  |
| Tesch, 2023 | 641407 | 1907992 | 287 | 233 |  | 44.75 | 12.21 | 1.24\* | 1.04-1.04 |  |
| Primary biliary cirrhosis | Tesch, 2023 | 641407 | 1907992 | 40 | 32 |  | 6.24 | 1.68 | 1.24\* | 0.78-0.78 |  |
| Psoriasis | Chang, 2023 | 887455 | 887455 | 1967 | 734 |  | 221.65 | 82.71 | 2.91^ | 2.67-2.67 |  |
| Tesch, 2023 | 641407 | 1907992 | 1519 | 1299 |  | 236.82 | 68.08 | 1.17\* | 1.09-1.09 |  |
| Rheumatoid arthritis | Chang, 2023 | 887455 | 887455 | 2878 | 1044 |  | 324.3 | 117.64 | 2.98^ | 2.78-2.78 |  |
| Tesch, 2023 | 641407 | 1907992 | 1175 | 826 |  | 183.19 | 43.29 | 1.42\* | 1.3-1.3 |  |
| Sjögren's syndrome | Chang, 2023 | 887455 | 887455 | 727 | 301 |  | 81.92 | 33.92 | 2.62^ | 2.29-2.29 |  |
| Tesch, 2023 | 641407 | 1907992 | 604 | 419 |  | 94.17 | 21.96 | 1.44\* | 1.27-1.27 |  |
| Systemic lupus erythematosus | Chang, 2023 | 887455 | 887455 | 1189 | 429 |  | 133.98 | 48.34 | 2.99^ | 2.68-2.68 |  |
| Tesch, 2023 | 641407 | 1907992 | 63 | 47 |  | 9.82 | 2.46 | 1.34\* | 0.92-0.92 |  |
| Systemic sclerosis | Chang, 2023 | 887455 | 887455 | 222 | 93 |  | 25.02 | 10.48 | 2.58^ | 2.02-2.02 |  |
| Tesch, 2023 | 641407 | 1907992 | 35 | 50 |  | 5.46 | 2.62 | 0.70\* | 0.45-0.45 |  |
| Transverse myelitis | Xu, 2022 | 154068 | 5638795 |  |  |  |  |  | 1.49^ | 1.11-1.11 |  |
| Type 1 diabetes mellitus | Chang, 2023 | 887455 | 887455 | 3263 | 1318 |  | 367.68 | 148.51 | 2.68^ | 2.51-2.51 |  |
| McKeigue, 2023 | 36508 | 1484331 | 38 | 1005 |  | 104.09 | 67.71 | 0.86\* | 0.62-0.62 |  |
| Tesch, 2023 | 641407 | 1907992 | 381 | 304 |  | 59.4 | 15.93 | 1.25\* | 1.08-1.08 |  |
| Zareini, 2023 | 338670 | 1004688 | 19 | 83 |  | 5.61 | 8.26 | 0.69^ | 0.42-0.42 |  |
| Type 1 diabetes mellitus (Pediatric) | Kompaniyets, 2022 | 396336 | 792672 | 349 | 641 |  | 88.06 | 80.87 | 1.10^ | 0.96-0.96 |  |
| Noorzae, 2023 | 720592 | 1044727 | 144 | 469 |  | 19.98 | 44.89 | 0.85^ | 0.7-0.7 |  |
| Ulcerative colitis | Tesch, 2023 | 641407 | 1907992 | 367 | 282 |  | 57.22 | 14.78 | 1.30\* | 1.12-1.12 |  |
| Vasculitis | Chang, 2023 | 887455 | 887455 | 800 | 444 |  | 90.15 | 50.03 | 1.96^ | 1.74-1.74 |  |
| Vitiligo | Tesch, 2023 | 641407 | 1907992 | 132 | 97 |  | 20.58 | 5.08 | 1.36\* | 1.05-1.05 |  |
| Wegener’s disease | Tesch, 2023 | 641407 | 1907992 | 41 | 16 |  | 6.39 | 0.84 | 2.51\* | 1.42-1.42 |  |

Exp. = Exposed; Non Exp = Non Exposed; \* = Hazard Ratio (HR),; ^ = Incidence Rate Ratio (IRR); 95% CI = 95% Confidence Interval. Ref = Reference.